Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 125Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 81Etoposide 73Filgrastim 64Mycophenolic Acid 63Tacrolimus 57Whole-Body Irradiation 55Busulfan 52Doxorubicin 50Radiotherapy 48Melphalan 48Cyclosporine 47Brentuximab Vedotin 45Rituximab 39Vinblastine 37fludarabine 36Granulocyte Colony-Stimulating Factor 36Antilymphocyte Serum 35Prednisone 33Methotrexate 32Vincristine 31Gemcitabine 30Dacarbazine 29Bleomycin 29Cytarabine 26Carmustine 22Bendamustine Hydrochloride 21Sirolimus 18Ifosfamide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hodgkin Disease × obatoclax × Clear all
NCT00359892 2012-08-06

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
13 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡